This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (35)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Lee M. Jampol, MD; James Tielsch, PhD

Arch Ophthalmol. 1992;110(12):1699-1700.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The Macular Photocoagulation Study (MPS) is a multicenter, collaborative, clinical trial that provides important guidelines for the treatment of choroidal neovascularization from age-related macular degeneration (AMD), presumed ocular histoplasmosis syndrome (POHS), and idiopathic neovascularization. In a previous editorial, Jampol¹ discussed the role of hypertension among patients in the MPS, showing that under some circumstances, patients with hypertension had a less beneficial response to laser photocoagulation. Another aspect of the MPS that has received almost no attention to date is the racial characteristics of patients enrolled in the trial.

See also p 1701.

The MPS includes three clinical trials for AMD: argon-laser photocoagulation for extrafoveal membranes, krypton-laser photocoagulation for juxtafoveal membranes, and argon or krypton laser photocoagulation for subfoveal membranes. As of July 1,1991, a total of 1319 patients had been enrolled in these trials (Maureen Maguire, PhD, written communication). Of these patients, 1314 were white, one was black, and . . . [Full Text PDF of this Article]

Author Affiliations
Chicago, Ill; Baltimore, Md

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?